What counts as a “major” patent expiry, and how soon is “soon”?
“Major” drug patents usually means patents tied to widely used branded medicines and/or major revenue categories. “Soon” is typically read as expirations within the next few years (often the next 12–36 months), because that’s when generic or biosimilar companies may be able to launch products if regulatory exclusivities also end.
Because patent expiry dates depend on jurisdiction and the specific patent in the brand’s patent “family,” it’s common to track each brand’s last-to-expire patents by market.
Which drug patent expiries are being tracked right now?
DrugPatentWatch.com publishes an ongoing view of drug patent status by brand, including key patents and estimated expiry timing. You can use it to find “expiring soon” matches by browsing their listings and filtering by time horizon: https://www.drugpatentwatch.com/
Why patents may not be the full story: exclusivity vs. patent expiry
Even after a patent expires, some drugs remain protected by other forms of regulatory exclusivity (for example, periods of data or market exclusivity) that can delay generic or biosimilar entry. That’s why “set to expire soon” is often best interpreted as “patent protection is approaching its end,” not “a cheaper version will launch immediately.”
How to pinpoint the most relevant expiring patents for your country
Expiry timing can differ by:
- Patent jurisdiction (US vs. EU vs. UK vs. other markets).
- Which specific patent is last to expire for each product.
- Patent term adjustments, extensions, or related litigation that can push effective protection out.
If you tell me the country/region you care about (US, EU, UK, etc.) and the time window (for example, “within 1 year” or “within 2–3 years”), I can narrow the list to the most relevant “expiring soon” major drug patents from the source above.
Sources:
1. https://www.drugpatentwatch.com/